BDB -BiopanningDataSet Details

Biopanning Data

BiopanningDataSet ID: 2805

Peptides:

Sequences	Affinity Values
ETCRASCINESA(13/20)	[1.22 ± 0.15]

Sequences Features:

Motif:

Unique Sequence Number:

Experimental Method:

Phage display (subtractive panning)

Sequencing Platform:

Sequencing Method:

Sanger sequencing

Rounds of Panning:

Reference:

PMID: 25324041

Target Name:

IgG from patients with CHB with HBsAg seroclearance following peg-IFN-α therapy

Template Name:

Not determined.

Structure of Target-Template Complex:

Not determined.

Structure of Target-Peptide Complex:

Not determined.

Library Name:

Ph.D.-12 phage display library (X12)

Affinity Measurement Method:

ELISA

Affinity Measurement Description:

The binding activities of positive phage clones to sera from chronic hepatitis B patients,with hepatitis B surface antigen (HBsAg) clearance, following pegylated interferon-α therapy were measured by phage ELISA. Absorbances were measured at 450 nm and data shown were reproduced from the Figure 1A in the reference. The original phage library was used as negative control, which had the value of 0.27 when binding to the sera. In ELISA experiment, the peptide ETCRASCINESA appeared 13 times and the affinity value was presented as mean ± standard deviation.

Brief Description:

To increase the screening specificity, microtiter wells were coated with purified sera IgG from the patients with CHB without HBsAg seroclearance, in order to absorb non-specific phages from the random phage peptide library. The unbound phages were then incubated with the sera IgG from patients with CHB, with HBsAg seroclearance, to screen for phage containing potential peptide biomarkers.

BiopanningDataSet Comments:

In the validation phase, phage-ELISA results showed that the positive reaction rate of the ETCRASCINESA (named IFNC1) peptide phage clone was 92.0% with the HBsAg seroclearance group (n=50), which was significantly higher, as compared with the randomly selected HBsAg non-clearance group (12.0%, n=50) and the healthy control group (8.0%, n=50). The newly identified mimic peptide IFNC1 showed a high predictive validity HBsAg seroclearance in patients with CHB, following peg-IFN-α therapy. Therefore IFNC1 may be a potential serum biomarker, which could be used to predict the treatment outcomes of peg-IFN-α therapy.

Curator:

Curation Date:

0000-00-00

First |

Prev |

2805

| Next

| Last